Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
6fEe7GeA8xNwPqh5
